Your browser is no longer supported. Please, upgrade your browser.
BIO [NYSE]
Bio-Rad Laboratories, Inc.
IndexS&P 500 P/E3.40 EPS (ttm)220.42 Insider Own1.80% Shs Outstand29.81M Perf Week-3.49%
Market Cap22.29B Forward P/E54.23 EPS next Y13.82 Insider Trans-2.79% Shs Float21.49M Perf Month-4.98%
Income6.66B PEG0.19 EPS next Q3.50 Inst Own79.90% Short Float2.97% Perf Quarter-7.86%
Sales2.98B P/S7.48 EPS this Y116.60% Inst Trans0.03% Short Ratio5.43 Perf Half Y28.91%
Book/sh514.27 P/B1.46 EPS next Y-11.18% ROA43.00% Target Price918.75 Perf Year40.09%
Cash/sh44.96 P/C16.67 EPS next 5Y17.80% ROE56.20% 52W Range521.40 - 832.70 Perf YTD28.58%
Dividend- P/FCF33.45 EPS past 5Y101.00% ROI-6.90% 52W High-9.98% Beta0.86
Dividend %- Quick Ratio2.90 Sales past 5Y4.70% Gross Margin57.90% 52W Low43.76% ATR19.73
Employees8000 Current Ratio3.80 Sales Q/Q15.40% Oper. Margin18.70% RSI (14)47.46 Volatility2.38% 2.57%
OptionableYes Debt/Eq0.00 EPS Q/Q197.80% Profit Margin- Rel Volume0.70 Prev Close750.17
ShortableYes LT Debt/Eq0.00 EarningsOct 28 AMC Payout0.00% Avg Volume117.48K Price749.56
Recom1.50 SMA20-1.33% SMA50-0.64% SMA20010.60% Volume82,404 Change-0.08%
Jan-08-20Initiated Wells Fargo Overweight $430
Jan-07-20Initiated Citigroup Buy $450
Oct-17-18Initiated Goldman Buy $350
Sep-20-18Initiated Morgan Stanley Equal-Weight $335
Feb-16-18Downgrade CL King Buy → Neutral
Jul-13-17Initiated Wells Fargo Outperform
Jun-28-17Upgrade Deutsche Bank Hold → Buy $220 → $255
Jan-18-17Initiated Deutsche Bank Hold $195
Oct-13-16Initiated CL King Buy
May-06-15Reiterated Jefferies Buy $150 → $165
Dec-18-09Initiated Maxim Group Buy $125
Nov-06-09Initiated Jefferies & Co Buy $130
Jul-17-09Initiated Soleil Buy $91
Sep-26-07Initiated Banc of America Sec Buy $110
Feb-23-07Downgrade Robert W. Baird Outperform → Neutral $83 → $76
Nov-29-21 01:34PM  
Nov-25-21 08:59AM  
07:16AM  
Nov-22-21 11:05AM  
Nov-15-21 08:46AM  
Nov-11-21 10:46AM  
Nov-04-21 08:50AM  
Oct-29-21 10:37AM  
Oct-28-21 09:01PM  
05:55PM  
04:15PM  
Oct-27-21 07:01AM  
Oct-22-21 10:12AM  
Oct-21-21 03:03PM  
Oct-20-21 10:13AM  
Oct-19-21 09:25AM  
Oct-15-21 08:00AM  
Oct-12-21 11:12AM  
Sep-30-21 01:10PM  
Sep-18-21 10:34AM  
Sep-16-21 12:00PM  
Sep-14-21 12:00PM  
Sep-13-21 08:19AM  
Sep-09-21 08:21AM  
Sep-03-21 09:52AM  
Sep-02-21 09:08AM  
Aug-31-21 08:50AM  
08:00AM  
Aug-30-21 10:31AM  
Aug-27-21 08:17AM  
Aug-26-21 09:34AM  
Aug-24-21 09:05AM  
Aug-21-21 07:19AM  
Aug-19-21 08:46AM  
Aug-18-21 09:34AM  
Aug-17-21 10:30AM  
Aug-12-21 09:57AM  
Aug-11-21 12:20PM  
09:01AM  
Aug-10-21 09:57AM  
09:53AM  
Aug-09-21 01:00PM  
09:01AM  
08:50AM  
Aug-06-21 01:02PM  
12:39PM  
12:13PM  
Jul-30-21 10:22AM  
01:32AM  
Jul-29-21 05:35PM  
04:15PM  
Jul-27-21 12:27PM  
06:30AM  
Jul-23-21 07:01AM  
Jul-22-21 03:03PM  
Jul-14-21 04:15PM  
Jul-06-21 10:59AM  
Jun-30-21 05:00PM  
Jun-24-21 04:48PM  
Jun-21-21 11:51AM  
08:00AM  
Jun-18-21 09:58AM  
May-29-21 04:11PM  
May-20-21 08:30AM  
May-10-21 05:13PM  
11:11AM  
Apr-30-21 09:29AM  
05:31AM  
02:19AM  
Apr-29-21 05:45PM  
04:15PM  
Apr-28-21 05:32PM  
Apr-26-21 08:09AM  
Apr-22-21 12:33PM  
Apr-15-21 08:30AM  
Apr-13-21 09:36AM  
Apr-05-21 08:37AM  
Apr-01-21 09:18AM  
Mar-29-21 03:44PM  
Mar-26-21 12:24PM  
08:16AM  
Mar-22-21 06:18PM  
Mar-15-21 07:31AM  
Mar-13-21 11:30AM  
Mar-11-21 10:45AM  
Mar-05-21 04:16PM  
Feb-22-21 04:15PM  
Feb-12-21 09:19AM  
05:31AM  
05:29AM  
Feb-11-21 05:45PM  
04:52PM  
04:20PM  
Feb-10-21 10:30AM  
09:12AM  
Feb-08-21 09:51AM  
Feb-05-21 09:53AM  
Feb-04-21 04:10PM  
Jan-25-21 04:15PM  
Jan-21-21 08:00AM  
Bio-Rad Laboratories, Inc. develops, manufactures, and markets life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, and Latin America. The company offers products and systems to separate complex chemical and biological materials, as well as to identify, analyze, and purify components. It operates in two segments, Life Science and Clinical Diagnostics. The Life Science segment develops, manufactures, and markets a range of reagents, apparatus, and laboratory instruments that are used in research techniques, biopharmaceutical production processes, and food testing regimes. It focuses on selected segments of the life sciences market in proteomics, genomics, biopharmaceutical production, cell biology, and food safety. This segment serves universities and medical schools, industrial research organizations, government agencies, pharmaceutical manufacturers, biotechnology researchers, food producers, and food testing laboratories. The Clinical Diagnostics segment designs, manufactures, sells, and supports test systems, informatics systems, test kits, and specialized quality controls for clinical laboratories in the diagnostics market. This segment offers reagents, instruments, and software, which address specific niches within the in vitro diagnostics test market. It sells its products to reference laboratories, hospital laboratories, state newborn screening facilities, physicians' office laboratories, transfusion laboratories, and insurance and forensic testing laboratories. The company offers its products through its direct sales force, as well as through distributors, agents, brokers, and resellers. Bio-Rad Laboratories, Inc. was founded in 1952 and is headquartered in Hercules, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
TUMOLO ANNETTEExecutive Vice PresidentNov 12Option Exercise250.214,8001,201,0149,393Nov 15 10:55 AM
TUMOLO ANNETTEExecutive Vice PresidentNov 12Sale750.054,8003,600,2404,593Nov 15 10:55 AM
TUMOLO ANNETTEExecutive Vice PresidentNov 11Option Exercise386.821,546598,0296,139Nov 15 10:55 AM
TUMOLO ANNETTEExecutive Vice PresidentNov 11Sale749.001,5461,157,9584,593Nov 15 10:55 AM
SCHWARTZ NORMAN DChairman, President, and CEOSep 07Option Exercise92.5640,0003,702,220336,786Sep 09 09:39 AM
Crowley MichaelEVP, GBL Commercial OperationsSep 07Option Exercise0.0060005,371Sep 09 09:38 AM
TUMOLO ANNETTEExecutive Vice PresidentSep 07Option Exercise0.0060004,891Sep 09 09:38 AM
ERNST TIMOTHY SEVP, General Counsel & SecSep 07Option Exercise0.0050002,401Sep 09 09:37 AM
Crowley MichaelEVP, GBL Commercial OperationsSep 05Option Exercise0.0060005,069Sep 08 12:10 PM
SCHWARTZ NORMAN DChairman, President, and CEOSep 05Option Exercise0.002,6000424,960Sep 08 12:09 PM
ERNST TIMOTHY SEVP, General Counsel & SecSep 05Option Exercise0.0050002,149Sep 08 12:05 PM
TUMOLO ANNETTEExecutive Vice PresidentSep 05Option Exercise0.0060004,589Sep 08 12:06 PM
TUMOLO ANNETTEExecutive Vice PresidentSep 04Option Exercise0.0060004,287Sep 08 12:06 PM
ERNST TIMOTHY SEVP, General Counsel & SecSep 04Option Exercise0.0050001,897Sep 08 12:05 PM
SCHWARTZ NORMAN DChairman, President, and CEOSep 04Option Exercise0.002,6000423,650Sep 08 12:09 PM
Crowley MichaelEVP, GBL Commercial OperationsSep 04Option Exercise0.0060004,767Sep 08 12:10 PM
Crowley MichaelEVP, GBL Commercial OperationsSep 03Option Exercise0.0055704,444Sep 08 12:10 PM
SCHWARTZ NORMAN DChairman, President, and CEOSep 03Option Exercise0.002,3190422,200Sep 08 12:09 PM
ERNST TIMOTHY SEVP, General Counsel & SecSep 03Option Exercise0.0046401,619Sep 08 12:05 PM
TUMOLO ANNETTEExecutive Vice PresidentSep 03Option Exercise0.0055703,939Sep 08 12:06 PM
Daskal IlanEVP, Chief Financial OfficerSep 03Sale820.06270221,4169Sep 08 12:07 PM
SCHWARTZ NORMAN DChairman, President, and CEOSep 02Option Exercise0.001,8050420,776Sep 03 05:12 PM
TUMOLO ANNETTEExecutive Vice PresidentSep 02Option Exercise0.0043303,532Sep 03 05:10 PM
Crowley MichaelEVP, GBL Commercial OperationsSep 02Option Exercise0.0043304,102Sep 03 05:09 PM
RAMALINGAM AJITSVP, Chief Accounting OfficerSep 02Option Exercise0.002400473Sep 03 05:07 PM
WRIGHT DARAExecutive Vice PresidentSep 02Option Exercise0.004330761Sep 03 05:08 PM
Last Andrew J.EVP, Chief Operating OfficerSep 02Option Exercise0.0090202,184Sep 03 05:05 PM
Daskal IlanEVP, Chief Financial OfficerSep 02Option Exercise261.911,081283,122548Sep 03 05:02 PM
ERNST TIMOTHY SEVP, General Counsel & SecSep 02Option Exercise0.0036101,280Sep 03 05:01 PM
Daskal IlanEVP, Chief Financial OfficerSep 02Sale828.00540447,1217Sep 03 05:02 PM
Last Andrew J.EVP, Chief Operating OfficerSep 01Option Exercise299.242,000598,4803,282Sep 03 05:05 PM
Last Andrew J.EVP, Chief Operating OfficerSep 01Sale813.102,0001,626,2031,282Sep 03 05:05 PM
TUMOLO ANNETTEExecutive Vice PresidentAug 26Sale792.58600475,5483,099Aug 27 10:39 AM
Crowley MichaelEVP, GBL Commercial OperationsAug 09Option Exercise139.563,000418,6806,669Aug 10 11:58 AM
Crowley MichaelEVP, GBL Commercial OperationsAug 09Sale754.933,0002,264,7963,669Aug 10 11:58 AM
Daskal IlanEVP, Chief Financial OfficerAug 04Option Exercise309.841,400433,7762,307Aug 05 12:38 PM
ERNST TIMOTHY SEVP, General Counsel & SecAug 04Sale760.26327248,605919Aug 05 12:40 PM
Daskal IlanEVP, Chief Financial OfficerAug 04Sale751.842,3001,729,2417Aug 05 12:38 PM
RAMALINGAM AJITSVP, Chief Accounting OfficerApr 29Option Exercise0.002760318May 03 01:48 PM
Last Andrew J.EVP, Chief Operating OfficerApr 29Option Exercise0.001,00001,734Apr 30 02:31 PM
Daskal IlanEVP, Chief Financial OfficerApr 08Option Exercise0.0070001,157Apr 09 11:38 AM
ERNST TIMOTHY SEVP, General Counsel & SecFeb 19Option Exercise159.3240063,7282,143Feb 22 04:05 PM
ERNST TIMOTHY SEVP, General Counsel & SecFeb 19Sale640.77923591,4991,220Feb 22 04:05 PM
WRIGHT DARAExecutive Vice PresidentDec 16Option Exercise0.005020502Dec 17 04:34 PM
Crowley MichaelEVP, GBL Commercial OperationsDec 15Sale580.67374217,1713,669Dec 17 12:54 PM